Trial intelligence / Profile preview

Food Effect on PK of Darigabat in Healthy Adults

NCT02217787Phase 1Completed

Sponsor
Pfizer
Start
Sep 2014
Primary completion
Sep 2014
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of darigabat in epilepsy and generalized anxiety disorder (GAD) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 48 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration at 48 hours and 3 more. Started Sep 2014; status: completed.

02

Drugs

darigabat
03

Conditions

epilepsygeneralized anxiety disorder (GAD)

Beyond the preview

Go deeper on NCT02217787.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02217787.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call